Coenzyme Q10 effects in neurodegenerative disease

Spindler, Meredith; Beal, M. Flint; Henchcliffe, Claire

doi:10.2147/ndt.s5212

Cited by 83 publications

(38 citation statements)

References 94 publications

(136 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cerebrovascular disease is common in the elderly and is a well-recognized contributor to cognitive aging (Tsurio et al, 2003; Vermeer et al, 2003). Two other mechanisms that have been identified as possible causes of cognitive aging are oxidative stress and mitochondrial dysfunction (Golden et al, 2002; Liu et al, 2002; Spindler et al, 2009). Oxidative stress is a key feature of the cognitive aging process, and numerous studies have demonstrated a negative relationship between oxidative stress levels and cognitive performance in humans (Floyd and Hensley, 2002; Markesbery et al, 2005; Simpson et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…Oxidative stress is a key feature of the cognitive aging process, and numerous studies have demonstrated a negative relationship between oxidative stress levels and cognitive performance in humans (Floyd and Hensley, 2002; Markesbery et al, 2005; Simpson et al, 2015). Similarly, mitochondrial dysfunction has been linked to neurodegenerative disease in a range of studies including: animal models, in vitro studies of mitochondria levels in patients, post-mortem pathology and neuroimaging (Spindler et al, 2009). It has been proposed that interventions reducing oxidative stress levels and mitochondrial dysfunction can mitigate oxidative damage, slow the rate of aging, and reduce the incidence of neurological disease (Spindler et al, 2009; Simpson et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Stough

Nankivell

Camfield

et al. 2019

Front. Aging Neurosci.

View full text Add to dashboard Cite

Introduction : With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ 10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress. Methods and Analysis : We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA). Discussion : This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group. Clinical Trial Registration : The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Stough

Nankivell

Camfield

et al. 2019

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…This led to reduced cell dysfunction and death, which is a characteristic of the aforementioned neurodegenerative diseases (Somayajulu et al, 2005). In studies with animal models, results confirmed its neuroprotective role (Spindler, Beal, & Henchcliffe, 2009). Indeed, CoQ10 was not only capable of protecting neuronal cells from oxidative damage in a Parkinson's disease model (S. Sharma et al, 2004), but also reduced -amyloid plaque in transgenic mouse models of Alzheimer disease (X.…”

Section: Neurodegenerative Diseasesmentioning

confidence: 65%

Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges

Arenas-Jal

Suñé-Negre

García-Montoya

2020

Comp Rev Food Sci Food Safe

130

View full text Add to dashboard Cite

World population growth and aging are posing unprecedented challenges in sustaining the health of 9.1 billion people that will be occupying the planet by 2050. Although noncommunicable diseases such as cardiovascular and neurodegenerative diseases, cancer, and diabetes are among the top 10 global causes of death, they can be prevented by risk factor reduction, early detection, and adequate treatment. Since a healthy diet along with dietary supplementation could play an important role to reduce morbidity and cut off its associated health care costs, research in the food and nutrition area is required to find solutions to global challenges affecting health. As a result of the healthy living trend, dietary supplements category is growing fast, leading to an urgent need for dietitians, physicians, and policy makers to broaden the scientific evidence on the efficacy and safety of a wide range of active ingredients. Coenzyme Q10 (CoQ10), as the third most consumed dietary supplement, and as a potential candidate for the treatment of various noncommunicable diseases that are among the global top 10 causes of death, has gained interest over years. Scientific evidence regarding mainly CoQ10 efficacy and safety, as well as formulation challenges, is addressed in this review.

show abstract

“…In addition, CoQ10 reduced the trend toward cognitive and functional decline. Moreover, several clinical trials for Parkinson’s disease, Alzheimer disease, amyotrophic lateral sclerosis and Friedreich ataxia demonstrated the potential neuroprotective effects of CoQ10 (39). …”

Section: Discussionmentioning

confidence: 99%

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease

Lopes‐Ramos

Pereira

Dogini

et al. 2016

Braz J Med Biol Res

View full text Add to dashboard Cite

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by expansion of the polyglutamine domain of the ataxin-3 (ATX3) protein. MJD/SCA3 is the most frequent autosomal dominant ataxia in many countries. The mechanism underlying MJD/SCA3 is thought to be mainly related to protein misfolding and aggregation leading to neuronal dysfunction followed by cell death. Currently, there are no effective treatments for patients with MJD/SCA3. Here, we report on the potential use of lithium carbonate and coenzyme Q10 to reduce cell death caused by the expanded ATX3 in cell culture. Cell viability and apoptosis were evaluated by MTT assay and by flow cytometry after staining with annexin V-FITC/propidium iodide. Treatment with lithium carbonate and coenzyme Q10 led to a significant increase in viability of cells expressing expanded ATX3 (Q84). In addition, we found that the increase in cell viability resulted from a significant reduction in the proportion of apoptotic cells. Furthermore, there was a significant change in the expanded ATX3 monomer/aggregate ratio after lithium carbonate and coenzyme Q10 treatment, with an increase in the monomer fraction and decrease in aggregates. The safety and tolerance of both drugs are well established; thus, our results indicate that lithium carbonate and coenzyme Q10 are good candidates for further in vivo therapeutic trials.

show abstract

Coenzyme Q10 effects in neurodegenerative disease

Cited by 83 publications

References 94 publications

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease

Contact Info

Product

Resources

About